Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents No significant financial relationships to ...
Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 No significant financial relationships to disclose. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results